[go: up one dir, main page]

BRPI0607531A2 - métodos, composições e artigos de fabricação para intensificação da capacidade de sobrevivência de células, tecidos, órgãos e organismos - Google Patents

métodos, composições e artigos de fabricação para intensificação da capacidade de sobrevivência de células, tecidos, órgãos e organismos

Info

Publication number
BRPI0607531A2
BRPI0607531A2 BRPI0607531-2A BRPI0607531A BRPI0607531A2 BR PI0607531 A2 BRPI0607531 A2 BR PI0607531A2 BR PI0607531 A BRPI0607531 A BR PI0607531A BR PI0607531 A2 BRPI0607531 A2 BR PI0607531A2
Authority
BR
Brazil
Prior art keywords
methods
organs
stasis
tissues
cells
Prior art date
Application number
BRPI0607531-2A
Other languages
English (en)
Inventor
Mark B Roth
Mike Morrison
Dana Miller
Eric Blackstone
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of BRPI0607531A2 publication Critical patent/BRPI0607531A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MéTODOS, COMPOSIçõES E ARTIGOS DE FABRICAçãO PARA INTENSIFICAçãO DA CAPACIDADE DE SOBREVIVêNCIA DE CéLULAS, TECIDOS, ORGáOS E ORGANISMOS. A presente invenção refere-se ao uso de antagonistas de oxigênio e outros compostos ativos para indução de estase ou pré-estase em células, tecidos e/ou órgáos in vivo ou em um organismo em geral, além de intensificação de sua capacidade de sobrevivência. Ela inclui composições, métodos, artigos de fabricação e aparelhos para intensificação da capacidade de sobrevivência e para obtenção de estase ou pré-estase em qualquer um desses materiais biológicos, de modo a conservar e/ou proteger os mesmos. Em modalidades específicas, há também métodos terapêuticos e aparelhos para transplante de árgão, hipertermia, cicatrização de feridas, choque hemorrágico, cardioplegia ou cirurgia de desvio, neurodegeneração, hipotermia e câncer usando os compostos ativos descritos.
BRPI0607531-2A 2005-04-20 2006-04-20 métodos, composições e artigos de fabricação para intensificação da capacidade de sobrevivência de células, tecidos, órgãos e organismos BRPI0607531A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US67303705P 2005-04-20 2005-04-20
US67329505P 2005-04-20 2005-04-20
US71307305P 2005-08-31 2005-08-31
US73154905P 2005-10-28 2005-10-28
US76246206P 2006-01-26 2006-01-26
PCT/US2006/015158 WO2006113914A2 (en) 2005-04-20 2006-04-20 Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms

Publications (1)

Publication Number Publication Date
BRPI0607531A2 true BRPI0607531A2 (pt) 2009-09-15

Family

ID=36764069

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607531-2A BRPI0607531A2 (pt) 2005-04-20 2006-04-20 métodos, composições e artigos de fabricação para intensificação da capacidade de sobrevivência de células, tecidos, órgãos e organismos

Country Status (12)

Country Link
US (5) US8822535B2 (pt)
EP (1) EP1879599B1 (pt)
JP (1) JP2008538569A (pt)
AU (1) AU2006236150A1 (pt)
BR (1) BRPI0607531A2 (pt)
CA (1) CA2605631A1 (pt)
ES (1) ES2443653T3 (pt)
IL (1) IL186814A0 (pt)
MX (1) MX2007013196A (pt)
PL (1) PL1879599T3 (pt)
PT (1) PT1879599E (pt)
WO (1) WO2006113914A2 (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828226B2 (en) 2003-03-01 2014-09-09 The Trustees Of Boston University System for assessing the efficacy of stored red blood cells using microvascular networks
US7455812B2 (en) * 2003-10-16 2008-11-25 Rheoxtech, Llc Method and apparatus for controlled reoxygenation
US20050136125A1 (en) * 2003-10-22 2005-06-23 Roth Mark B. Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
AU2004285468B2 (en) * 2003-10-22 2011-02-24 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
EP1879599B1 (en) 2005-04-20 2013-10-16 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
MX382184B (es) 2006-01-27 2025-03-13 Univ California Cisteamina recubierta entericamente, cistamina y derivados de ellas.
US11684510B2 (en) 2006-04-20 2023-06-27 University of Pittsburgh—of the Commonwealth System of Higher Education Noninvasive, regional brain thermal stimuli for the treatment of neurological disorders
US20170252534A1 (en) * 2006-04-20 2017-09-07 Eric Allan NOFZINGER Forehead cooling method and device to stimulate the parasympathetic nervous system for the treatment of insomnia
US8425583B2 (en) 2006-04-20 2013-04-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods, devices and systems for treating insomnia by inducing frontal cerebral hypothermia
JP2009534422A (ja) * 2006-04-20 2009-09-24 フレッド ハッチンソン キャンサー リサーチ センター ショックおよび他の有害な病態を処置するためのカルゴゲニドの使用
US12290640B2 (en) 2006-04-20 2025-05-06 University of Pittsburgh—of the Commonwealth System of Higher Education Noninvasive, regional brain thermal stimulation for inducing relaxation
US20090011051A1 (en) * 2006-09-28 2009-01-08 Roth Mark B Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds
US20080187604A1 (en) * 2006-10-05 2008-08-07 Ikaria, Inc. Liquid chalcogenide compositions and methods of manufacturing and using the same
US7923037B2 (en) 2006-10-05 2011-04-12 Ikaria, Inc. Liquid chalcogenide compositions and methods of manufacturing and using the same
WO2008070741A1 (en) * 2006-12-06 2008-06-12 Ikaria, Inc. Compositions and methods for enhancing survival and reducing injury under ischemic or hypoxic conditions
WO2008079993A2 (en) * 2006-12-22 2008-07-03 Ikaria, Inc. Combinations of nitric oxide and sulfide and methods of use and manufacture thereof
WO2008089439A2 (en) * 2007-01-18 2008-07-24 Fred Hutchinson Cancer Research Center Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
US20080318864A1 (en) * 2007-06-25 2008-12-25 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions
WO2009070781A1 (en) * 2007-11-30 2009-06-04 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
US20100031892A1 (en) * 2008-07-07 2010-02-11 Ilyin Ilya Y Method for storage of live crustaceans
WO2010005959A1 (en) * 2008-07-07 2010-01-14 Rich Products Corporation Method for treatment and storage of platelets
US8562585B2 (en) 2008-07-17 2013-10-22 Rheoxtech, Llc Method and apparatus for mitigating acute reoxygenation injury during percutaneous coronary intervention
GB0814419D0 (en) * 2008-08-08 2008-09-10 Health Smart Ltd Blood analysis
EP2370086A2 (en) * 2008-12-01 2011-10-05 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
US20100183748A1 (en) 2009-01-21 2010-07-22 Ikaria, Inc. Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury
US20100198338A1 (en) * 2009-01-30 2010-08-05 Medtronic Vascular, Inc., A Delaware Corporation Hydrogen Sulfide Donating Polymers
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US12089589B2 (en) 2009-10-12 2024-09-17 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
NZ622456A (en) 2009-10-12 2015-09-25 New Health Sciences Inc Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities
AU2010306920A1 (en) 2009-10-12 2012-05-31 New Health Sciences, Inc. Oxygen depletion devices and methods for removing oxygen from red blood cells
US8888737B2 (en) * 2009-10-20 2014-11-18 Rheoxtech, Llc Method and apparatus for cardiac tissue monitoring and catheter-based perfusion for mitigating acute reoxygenation injury
US8182830B2 (en) * 2010-01-05 2012-05-22 Medtronic Vascular, Inc. Hydrogen sulfide generating polymers
FR2956289B1 (fr) * 2010-02-18 2014-09-19 Air Liquide Formulation liquide avec gaz dissous utilisable pour conserver de la matiere biologique
US8604265B2 (en) * 2010-04-16 2013-12-10 Kci Licensing, Inc. Dressings and methods for treating a tissue site on a patient
EP4091645A1 (en) 2010-08-25 2022-11-23 Hemanext Inc. Method for enhancing red blood cell quality and survival during storage
PT2635114T (pt) 2010-11-05 2020-06-16 New Health Sciences Inc Irradiação de glóbulos vermelhos e armazenamento anaeróbico
US20140037760A1 (en) * 2011-03-17 2014-02-06 Jeff Thramann Methods of inducing stasis for the treatment of cancer
AU2012294890B2 (en) * 2011-03-28 2017-05-18 Hemanext Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
EP2532325B1 (de) * 2011-06-09 2014-03-05 Paul Hartmann AG Wundauflage, enhaltend Schaumstoff und Salbengrundlage und Quellstoff, zur Unterdrucktherapie
CA2844449A1 (en) 2011-08-10 2013-02-14 New Health Sciences, Inc. Integrated leukocyte, oxygen and/or co2 depletion, and plasma separation filter device
JP6046727B2 (ja) 2011-09-26 2016-12-21 アドバンスド プリザベイションズ テクノロジーズ リミテッド ライアビリティー カンパニー 生体組織の保存方法
GB201117095D0 (en) 2011-09-30 2011-11-16 Univ Exeter The Novel hydrogen sulfide releasing compounds
CN102550652A (zh) * 2012-01-10 2012-07-11 合肥工业大学 一种硫化氢供体硫氢化钠促进果蔬储藏保鲜的新用途
AU2013240277C1 (en) 2012-03-30 2018-06-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Measurement of biologically labile hydrogen sulfide pools
TW201420130A (zh) * 2012-09-26 2014-06-01 Neochemir Inc 溶解有二氧化碳之液狀藥劑及其投藥方法
US9210938B2 (en) 2012-11-28 2015-12-15 Elwha Llc Methods for modulating photosynthetic activity
CA2894161C (en) 2012-12-19 2022-08-02 Advanced Preservations Technologies, Llc Platelet concentrate preservation method
US10058674B2 (en) 2013-01-02 2018-08-28 Ebb Therapeutics, Inc. Systems for enhancing sleep
CA2902061C (en) 2013-02-28 2023-08-08 New Health Sciences, Inc. Gas depletion and gas addition devices for blood treatment
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
US9526228B2 (en) * 2014-03-07 2016-12-27 Amirix Systems Inc. Predation detection fish tracking tag
US9919049B2 (en) 2014-06-02 2018-03-20 University Of Exeter Combinations of a photosensitizer with a hydrogen sulfide donor, thioredoxin inhibitor or nitroxide for use in photodynamic therapy
CA2903243C (en) 2014-11-19 2021-06-01 Amirix Systems Inc. Predation detection animal tracking tag
IL299978B2 (en) 2015-03-10 2024-08-01 Hemanext Inc Single-use oxygen reduction kits, devices and methods for their use
BR122022005103B1 (pt) 2015-04-23 2023-03-14 Hemanext Inc Dispositivo de armazenamento de sangue para armazenar sangue depletado de oxigênio e método para armazenar sangue depletado de oxigênio
RU2612913C2 (ru) * 2015-05-12 2017-03-13 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" Способ повышения продолжительности жизни моллюсков Abra segmentum в условиях гипоксии на период от 4 до 14 суток
EP3297641B1 (en) 2015-05-18 2025-07-09 Hemanext Inc. Methods for the storage of whole blood, and compositions thereof
US10537528B2 (en) 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
IL282627B2 (en) 2016-05-27 2023-10-01 Hemanext Inc Anaerobic blood storage and pathogen inactivation method
US11260437B2 (en) 2016-11-22 2022-03-01 Brian Michael Hays Cleaning and separating medical waste
EP4302768A3 (en) 2017-06-22 2024-05-01 Board Of Regents, The University Of Texas System Methods for producing regulatory immune cells and uses thereof
CN107827084A (zh) * 2017-12-07 2018-03-23 四川科比科油气工程有限公司 利于防泄漏的硫磺回收设备
TWI660078B (zh) * 2018-01-12 2019-05-21 孫敬閔 自穿山甲排遺進行篩洗及分析蟻類物種的方法
DK3755347T3 (da) 2018-02-21 2025-08-04 Univ Texas Universelle antigenpræsenterende celler og anvendelser deraf
EP3991737A4 (en) * 2019-06-28 2023-08-09 Sumitomo Seika Chemicals Co., Ltd. GAS COMPOSITION FOR USE IN WOUND TREATMENT, AND WOUND TREATMENT DEVICE
CN114072156A (zh) 2019-06-28 2022-02-18 国立研究开发法人物质·材料研究机构 皮肤创伤预防用和/或皮肤创伤治疗用构成体
EP4110050A1 (en) * 2020-02-26 2023-01-04 Finless Food Inc. Systems and methods for live fish tissue preservation
CN111700908A (zh) * 2020-05-22 2020-09-25 南开大学 一种纳米金属硫化物作为制备神经损伤修复药物的应用
CN112075415B (zh) * 2020-09-25 2021-08-31 中国科学院海洋研究所 一种冷冻保护液及刺参精子超低温冷冻保存方法
CN116019967B (zh) * 2023-03-02 2024-09-17 南昌大学第二附属医院 超弹蘑菇气凝胶及其制备方法和作为止血材料的应用

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1379855A (en) * 1921-05-31 Joseph donneb
US2031489A (en) * 1932-04-15 1936-02-18 Parfumerie St Denis Stable depilatory
US2435854A (en) * 1945-05-07 1948-02-10 Nasa Apparatus for the freezing-drying of tissues
US2487558A (en) * 1948-02-24 1949-11-08 Kamlet Jonas Cream depilatory and process for preparing same
US3587899A (en) * 1967-04-10 1971-06-28 Charles E Bender Freeze drying container
US3881990A (en) 1971-11-24 1975-05-06 Waters Instr Inc Method of transporting and storing organs while retaining the organs in a viable condition
US3777507A (en) * 1971-11-24 1973-12-11 Waters Instr Inc Renal preservation system
US3995444A (en) 1974-11-08 1976-12-07 American Hospital Supply Corporation Organ perfusion system
US4186565A (en) * 1978-05-19 1980-02-05 Henry Ford Hospital Perfusion system for organ preservation
US4292817A (en) * 1980-05-12 1981-10-06 The Mead Corporation Controlled temperature shipping assembly
DE3272969D1 (en) 1981-03-16 1986-10-09 Leonora I Jost Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells
US4377554A (en) 1981-08-26 1983-03-22 Becton, Dickinson And Company Generation of microaerophilic atmosphere
US4473637A (en) * 1982-11-10 1984-09-25 Guibert, Colman & Associates System for processing an organ preparatory to transplant
FR2559648B1 (fr) 1984-02-16 1988-07-08 Air Liquide Procede de conservation de denrees alimentaires vegetales perissables
US4502295A (en) * 1984-02-21 1985-03-05 Mount Carmel Research And Education Corporation Organ hypothermic storage unit
US4562051A (en) 1984-02-27 1985-12-31 Becton, Dickinson And Company Generation of anaerobic or microaerophilic atmosphere
EP0203730B1 (en) 1985-04-30 1993-06-23 Toray Industries, Inc. Anti-reflection optical article and process for preparation thereof
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
US4723974A (en) 1985-07-26 1988-02-09 Ammerman Stephen W Transporting container for an amputated extremity
US4798824A (en) * 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5266480A (en) 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US4807442A (en) * 1986-12-03 1989-02-28 Board Of Regents The University Of Texas System Cryo-slamming apparatus and method for ultrarapid cooling of biological samples
US4745759A (en) 1986-12-23 1988-05-24 Bauer Dan O Kidney preservation machine
US5114842A (en) 1987-07-08 1992-05-19 The Scripps Research Institute Peptides and antibodies that inhibit platelet adhesion
US4923442A (en) * 1988-05-02 1990-05-08 Cryomedical Sciences Inc. Blood substitute
JPH0251404A (ja) 1988-05-31 1990-02-21 Sankyo Kasei Kk 無水硫化ナトリウム結晶の製造法
US4920044A (en) * 1988-11-08 1990-04-24 The Cleveland Clinic Foundation Intracellular flush solution for preserving organs
US4951482A (en) 1988-12-21 1990-08-28 Gilbert Gary L Hypothermic organ transport apparatus
US4938961A (en) * 1989-04-28 1990-07-03 Geoffrey Collins Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia
US5326706A (en) * 1989-07-17 1994-07-05 Research Foundation Of State University Of New York Homeostatic organ preservation system
DE69024187T2 (de) * 1989-07-27 1996-05-02 Leonora I Jost Biologischer unterstützungssystembehälter und verfahren zur konservierung von lebenden zellmaterialien von säugetieren, ex vivo
US5231025A (en) * 1989-11-03 1993-07-27 The United States Of America As Represented By The Department Of Health And Human Services Anti-platelet monoclonal antibody
US5066578A (en) * 1989-12-21 1991-11-19 The Regents Of The University Of California Long-term preservation of organs for transplantation
FR2667297B1 (fr) 1990-09-28 1994-05-27 Electrolux Sarl Conteneur medical climatise.
US5584804A (en) * 1990-10-10 1996-12-17 Life Resuscitation Technologies, Inc. Brain resuscitation and organ preservation device and method for performing the same
US5395314A (en) * 1990-10-10 1995-03-07 Life Resuscitation Technologies, Inc. Brain resuscitation and organ preservation device and method for performing the same
US5569579A (en) * 1991-04-01 1996-10-29 Thomas Jefferson University Synthetic-based platelet storage media
US5157930A (en) 1991-04-22 1992-10-27 Mcghee Samuel C Organ preservation apparatus
US5328821A (en) * 1991-12-12 1994-07-12 Robyn Fisher Cold and cryo-preservation methods for human tissue slices
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5370989A (en) 1992-04-03 1994-12-06 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5350745A (en) * 1993-01-29 1994-09-27 Lunar Corporation Treatment of myocardial failure
JP2708964B2 (ja) 1993-01-29 1998-02-04 シェリング−プラウ・ヘルスケア・プロダクツ・インコーポレーテッド 安定な硫化組成物、その利用及び製造方法
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5464768A (en) * 1993-02-24 1995-11-07 The United States Of America As Represented By The Secretary Of The Air Force Enhanced nitrite production in transfected murine cells
US5599659A (en) * 1993-03-11 1997-02-04 Breonics, Inc. Preservation solution for ex vivo, warm preservation of tissues, explants,organs and vascular endothelial cells comprising retinal-derived fibroblast growth factor, cyclodextrin and chondroitin sulfate
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
KR100267604B1 (ko) * 1993-06-04 2000-11-01 이 세갈 폴 혈장 유사 용액
SE9302431D0 (sv) * 1993-07-16 1993-07-16 Ab Astra Use of indenoindole compounds
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
DK0726768T3 (da) * 1993-11-02 2000-10-02 Us Health Anvendelse af nitrogenoxidfrigørende forbindelser til fremstillingen af et medikament til beskyttelse i iskæmisk reperfusio
US5770583A (en) * 1994-01-25 1998-06-23 Schering-Plough Healthcare Products, Inc. Stable sulfide compositions uses and process for preparation thereof
EP0759692B1 (en) 1994-05-20 2009-02-25 Breonics, Inc. Method monitoring viability of transplantable organs
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5476764A (en) 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US5635344A (en) * 1994-12-07 1997-06-03 Cedra Corp. Shipping medium for organ-derived cells
US5554497A (en) 1994-12-12 1996-09-10 Charlotte-Mecklenburg Hospital Authority Cardioplegic solution for arresting an organ
JP3543869B2 (ja) * 1995-03-07 2004-07-21 株式会社メニコン 培養皮膚およびその製造法
EP0738766B1 (en) * 1995-04-20 2001-07-25 Clariant Finance (BVI) Limited Stable liquid suspensions of sulphur dyes and method for analyzing same
US5791151A (en) * 1995-06-07 1998-08-11 Verhaag; Hubert Method of preserving tissues and organs
DE19654895C2 (de) * 1996-02-07 2000-07-27 Sanol Arznei Schwarz Gmbh Detektionsverfahren
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
US5912019A (en) * 1997-02-07 1999-06-15 Musc Foundation For Research Development Compounds for reducing ischemia/reperfusion injury
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
ES2239801T3 (es) * 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
US6164276A (en) 1997-05-16 2000-12-26 Datex-Ohmeda, Inc. Accurate dose nitric oxide pulse delivery device with monitoring and alarms
US6100082A (en) * 1997-09-23 2000-08-08 Hassanein; Waleed H. Perfusion apparatus and method including chemical compositions for maintaining an organ
US6109260A (en) * 1998-02-18 2000-08-29 Datex-Ohmeda, Inc. Nitric oxide administration device with timed pulse
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
FR2785501B1 (fr) * 1998-11-10 2001-01-05 Centre Nat Rech Scient Solution de perfusion et/ou de conservation et/ou de reperfusion lors de la transplantation d'organes
US6713108B2 (en) 1998-12-17 2004-03-30 Freezing Machines, Inc. Method for producing a pH enhanced comminuted meat product
ZA99535B (en) * 1999-01-25 2000-01-26 William Du Toit Oxygen generating device.
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US6365338B1 (en) * 1999-04-27 2002-04-02 David A. Bull Organ preservative solution containing trehalose, anti-oxidant, cations and an energy source
RU2177774C2 (ru) 1999-04-29 2002-01-10 Научно-исследовательский центр курортологии и реабилитации (г.Сочи) Черноморского зонального управления специализированных санаториев МЗ РФ Способ лечения ишемической болезни сердца, стенокардии напряжения i-ii функциональных классов
FR2793651B1 (fr) * 1999-05-18 2003-05-16 Cair L G L Solution aqueuse de conservation de tissus et d'organes
EP1197210B1 (en) * 1999-07-16 2005-10-05 Kissei Pharmaceutical Co., Ltd. Agents inhibiting chronic rejection reactions after organ transplantation
RU2177299C2 (ru) 1999-07-29 2001-12-27 Научно-исследовательский центр курортологии и реабилитации (г.Сочи) Черноморского зонального управления специализированных санаториев Способ лечения ишемической болезни сердца, стенокардии напряжения i-ii функциональных классов
US6492103B1 (en) 2000-01-31 2002-12-10 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
WO2001060411A1 (en) * 2000-02-18 2001-08-23 Kanagawa Academy Of Science And Technology Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
WO2001081546A2 (en) * 2000-04-26 2001-11-01 Massachusetts Institute Of Technology CeSERT GENES, PROTEINS, AND MODULATORY COMPOUNDS
AU2001265996A1 (en) * 2000-05-27 2001-12-11 Exelixis Deutschland Gmbh Method for the identification of agents and genes influencing cardiovascular function
AU2001275429B2 (en) * 2000-06-09 2005-12-08 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for manipulating the thermoregulatory status
US6557492B1 (en) * 2002-07-19 2003-05-06 Sea Chick, Inc. System for transporting and storing live fish, components thereof and methods based thereon
US20030185901A1 (en) * 2000-07-27 2003-10-02 Burrell Robert E. Methods of treating conditions with a metal-containing material
JP4882054B2 (ja) 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
US6490880B1 (en) 2000-10-26 2002-12-10 Islet Technology Inc. Regulated organ containment shipping system using dual-layer preservation liquid
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
GB2374008B (en) * 2001-04-04 2005-03-16 John Carter Pharmaceutical compositions comprising copper and zinc
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
WO2002096387A1 (en) * 2001-05-25 2002-12-05 Medtronic, Inc. Implantable medical device with controllable gaseous agent release system
AU2002312458A1 (en) * 2001-06-11 2002-12-23 Fred Hutchinson Cancer Research Center Methods for inducing reversible stasis
JP3816767B2 (ja) * 2001-07-30 2006-08-30 独立行政法人科学技術振興機構 ポルフィリン金属錯体とそれを含有する酸素輸液
CA2468083C (en) * 2001-12-06 2016-02-23 Fibrogen, Inc. Use of heterocyclic carboxamides to treat anemia
GB0206711D0 (en) * 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
IL149611A (en) * 2002-05-13 2011-07-31 Safetin Ltd Method for extended storage of viable and pathogen-safe blood and blood components using carbon monoxide
US20030235571A1 (en) 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
MXPA04012863A (es) * 2002-06-21 2005-03-31 Univ Pittsburgh Uso farmaceutico de oxido nitrico, heme oxigenasa-1 y productos de degradacion de heme.
WO2004060147A2 (en) * 2002-12-31 2004-07-22 The Board Of Trustees Of The University Of Illinois Tissue and organ preservation, protection and resuscitation
DE10306766A1 (de) * 2003-02-18 2004-08-26 Ino Therapeutics Gmbh Dosierte Abgabe eines therapeutischen Gases
US6857443B2 (en) * 2003-02-24 2005-02-22 George A. Volgyesi Electronic gas blender and gas flow control mechanism therefor
JP2006527200A (ja) 2003-06-06 2006-11-30 ファイブロゲン インコーポレイティッド 窒素含有ヘテロアリール化合物および内因性エリトロポエチンを増加させる際のそれらの使用方法
US20050170019A1 (en) * 2003-10-22 2005-08-04 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
US20050136125A1 (en) * 2003-10-22 2005-06-23 Roth Mark B. Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
US20080085329A1 (en) * 2003-10-22 2008-04-10 Fred Hutchinson Cancer Research Center, Inc. Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms
AU2004285468B2 (en) * 2003-10-22 2011-02-24 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
US20050217667A1 (en) * 2004-03-30 2005-10-06 Sunil Dhuper Aerosol deliver apparatus IV
WO2005115075A2 (en) * 2004-05-27 2005-12-08 Antibe Therapeutics Inc. Salt of 4- or 5- aminosalicylic acid
US7216398B2 (en) * 2004-10-25 2007-05-15 Benext Inno-Product Development Ltd. Computer mouse with a cleaning function
EP1879599B1 (en) 2005-04-20 2013-10-16 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
US20070265223A1 (en) * 2006-03-10 2007-11-15 Ikaria, Inc. Compositions and methods of enhancing survivability and reducing injury of cells, tissues, organs, and organisms under hypoxic or ischemic conditions
JP2009534422A (ja) * 2006-04-20 2009-09-24 フレッド ハッチンソン キャンサー リサーチ センター ショックおよび他の有害な病態を処置するためのカルゴゲニドの使用
US7923037B2 (en) * 2006-10-05 2011-04-12 Ikaria, Inc. Liquid chalcogenide compositions and methods of manufacturing and using the same
US20080187604A1 (en) * 2006-10-05 2008-08-07 Ikaria, Inc. Liquid chalcogenide compositions and methods of manufacturing and using the same
WO2008079993A2 (en) * 2006-12-22 2008-07-03 Ikaria, Inc. Combinations of nitric oxide and sulfide and methods of use and manufacture thereof
JP2010530001A (ja) * 2007-06-15 2010-09-02 イカリア， インコーポレイテッド 硫化物単独または一酸化窒素との組み合わせを含む組成物およびその使用
US20080318864A1 (en) 2007-06-25 2008-12-25 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions
US8680151B2 (en) * 2010-02-11 2014-03-25 Fred Hutchinson Cancer Research Center Compounds, compositions and methods for treating or preventing hypoxic or ischemic injury

Also Published As

Publication number Publication date
US20080171726A1 (en) 2008-07-17
EP1879599A2 (en) 2008-01-23
PT1879599E (pt) 2014-01-23
PL1879599T3 (pl) 2014-03-31
CA2605631A1 (en) 2006-10-26
JP2008538569A (ja) 2008-10-30
MX2007013196A (es) 2008-01-18
WO2006113914A2 (en) 2006-10-26
US20070078113A1 (en) 2007-04-05
US20080171725A1 (en) 2008-07-17
IL186814A0 (en) 2008-02-09
US20120040024A1 (en) 2012-02-16
US8822535B2 (en) 2014-09-02
EP1879599B1 (en) 2013-10-16
US20160361356A1 (en) 2016-12-15
ES2443653T3 (es) 2014-02-20
WO2006113914A3 (en) 2007-04-19
AU2006236150A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
BRPI0607531A2 (pt) métodos, composições e artigos de fabricação para intensificação da capacidade de sobrevivência de células, tecidos, órgãos e organismos
BRPI0415752A (pt) métodos, composições e dispositivos para indução de estase em células, tecidos, órgãos e organismos
WO2008089439A3 (en) Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
MX2009001323A (es) Aposito solido para tratar tejido herido.
BRPI0410185A (pt) composição para manter a viabilidade de um orgão e célula
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
WO2006074410A3 (en) Three-dimensional implantable bone support
WO2007035843A3 (en) Methods and compositions for organ and tissue functionality
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
ATE428352T1 (de) Vorrichtungen zur platzierung von trennwänden in einem hohlen körperorgan
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
WO2005079822A3 (en) Pharmaceutical composition comprising a fibrin matrix and dermal fibroblasts for the treatment of wounds
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
ES2136673T3 (es) Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos.
WO2009047568A3 (en) In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
WO2008148474A3 (de) Lösungen für die perfusion und konservierung von organen und geweben
WO2006102643A3 (en) Stably transformed bone marrow-derived cells and uses thereof
WO2006023623A3 (en) Methods of healing wounds by administering human il-18
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]